DK3458480T3 - Antistof rettet mod endothelin-receptoren beta-subtype - Google Patents

Antistof rettet mod endothelin-receptoren beta-subtype Download PDF

Info

Publication number
DK3458480T3
DK3458480T3 DK17734032.0T DK17734032T DK3458480T3 DK 3458480 T3 DK3458480 T3 DK 3458480T3 DK 17734032 T DK17734032 T DK 17734032T DK 3458480 T3 DK3458480 T3 DK 3458480T3
Authority
DK
Denmark
Prior art keywords
endothelin receptor
receptor beta
antibody targeting
beta subtype
subtype
Prior art date
Application number
DK17734032.0T
Other languages
English (en)
Inventor
Didier Boquet
Frédéric Ducancel
Amaury Herbet
Narciso Costa
Jean-Philippe Hugnot
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of DK3458480T3 publication Critical patent/DK3458480T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17734032.0T 2016-06-24 2017-06-22 Antistof rettet mod endothelin-receptoren beta-subtype DK3458480T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655915A FR3053042B1 (fr) 2016-06-24 2016-06-24 Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations
PCT/EP2017/065442 WO2017220739A1 (en) 2016-06-24 2017-06-22 Antibody directed against the endothelin receptor beta sub-type

Publications (1)

Publication Number Publication Date
DK3458480T3 true DK3458480T3 (da) 2021-04-19

Family

ID=57583133

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17734032.0T DK3458480T3 (da) 2016-06-24 2017-06-22 Antistof rettet mod endothelin-receptoren beta-subtype

Country Status (10)

Country Link
US (1) US11312780B2 (da)
EP (1) EP3458480B1 (da)
JP (2) JP2019528041A (da)
DK (1) DK3458480T3 (da)
ES (1) ES2865300T3 (da)
FR (1) FR3053042B1 (da)
HU (1) HUE053695T2 (da)
PL (1) PL3458480T3 (da)
PT (1) PT3458480T (da)
WO (1) WO2017220739A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3077574B1 (fr) 2018-02-07 2022-04-01 Commissariat Energie Atomique Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
FR2965810B1 (fr) * 2010-10-06 2012-12-28 Commissariat Energie Atomique Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
JP2012111706A (ja) * 2010-11-24 2012-06-14 Sekisui Chem Co Ltd モノクローナル抗体、並びに、ハイブリドーマ
WO2013063001A1 (en) * 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma

Also Published As

Publication number Publication date
PL3458480T3 (pl) 2021-09-20
JP2022095888A (ja) 2022-06-28
WO2017220739A1 (en) 2017-12-28
FR3053042A1 (fr) 2017-12-29
US20190185574A1 (en) 2019-06-20
FR3053042B1 (fr) 2018-08-10
HUE053695T2 (hu) 2021-07-28
EP3458480A1 (en) 2019-03-27
JP2019528041A (ja) 2019-10-10
EP3458480B1 (en) 2021-01-27
US11312780B2 (en) 2022-04-26
ES2865300T3 (es) 2021-10-15
PT3458480T (pt) 2021-04-28

Similar Documents

Publication Publication Date Title
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
DK3283110T3 (da) Antistoffer rettet mod interleukin-36-receptor (il-36r)
DK3592393T3 (da) Frigørbare konjugater
DK3294764T3 (da) Kimæriske antigenreceptor sammensætninger
DK3579883T3 (da) Pyrrolobenzodiazepin-antistofkonjugater
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3274366T3 (da) Kimær antigenreceptor
CL2016002196A1 (es) Receptor antigénico quimérico
BR112018004981A2 (pt) anticorpos anti-pró-miostatina/miostatina latente e usos destes.
BR112017011893A2 (pt) células t modificadas no receptor de antígeno quimérico direcionado para cs1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
DK3227339T3 (da) Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf
DK3575315T3 (da) Kimære antigenreceptorer
DK3300500T3 (da) Triazolagonister af apj-receptoren
BR112016016020A2 (pt) anticorpos dirigidos contra interleucina-33 (il-33)
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3612537T3 (da) Pyrrolobenzodiazepinkonjugater
DK3166973T3 (da) Immunstimulerende monoklonale antistoffer mod human interleukin-2
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3154587T3 (da) Konjugater omfattende et anti-egfr1-antistof
DK3544634T3 (da) MET-antistof-lægemiddelkonjugater
ZA201907673B (en) Bone-targeting antibodies
MA50654A (fr) Anticorps anti-pacap
DK3484921T3 (da) Anti-IL-22R antistoffer